Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Six scientists from the University of Oxford have joined the Royal Society as Fellows, including vaccine and cancer researcher Prof. Adrian Hill

None

Professor Adrian Hill, Director of the Jenner Institute (Nuffield Department of Medicine), has become a Fellow of the Royal Society for his leading role in the design and development of new vaccines for globally important infectious diseases over the course of over 25 years.

One of his most important developments has been the spin out of Vaccitech, which he co-founded in 2016, to capitalise on the discovery of ChAdOx. The chimp cold virus, ChAdOx, became a weapon of choice against what the World Health Organization called “Disease X” – a hypothetical future pathogen with epidemic or pandemic potential.

ChAdOx is a viral vector which safely mimics viral infection in human cells and elicit antibody and T cell responses to pathogens and tumours. Thus far, ChAdOx has already been applied in cancers (prostate), malaria, and most recently, the AstraZeneca-Oxford vaccine for Sars-Cov-2.

Through his work, Professor Hill has demonstrated the applications of adenoviruses in immunisation regimes supporting new vaccination approaches for a variety of disease, many of which have previously not had treatment options available.

Professor Hill becomes one of 6 new Oxford researchers to join the Royal Society. Read about them here.

Similar Stories

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year. Six new Oxford fellowships were announced, including two significant cancer projects.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Turing Fellowships for Oxford cancer researchers

Oxford Cancer community members will join the Turing network for 2021-2022 to further their research in cancer big data.